The ASXL1 mutation was defined as an adverse prognostic marker in AML [6], but we did not confirm a trend towards an inferior outcome in patients with ASXL1 or the ASXL1/SRSF2 co-mutation. The gene discussed is SRSF2; the disease is acute myeloid leukemia.